Free Trial
NASDAQ:CRGX

CARGO Therapeutics Q1 2024 Earnings Report

CARGO Therapeutics logo
$4.47 0.00 (0.00%)
As of 08/19/2025

CARGO Therapeutics EPS Results

Actual EPS
-$0.87
Consensus EPS
-$1.05
Beat/Miss
Beat by +$0.18
One Year Ago EPS
N/A

CARGO Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CARGO Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Tuesday, May 14, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

CARGO Therapeutics' Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled on Thursday, November 6, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

CARGO Therapeutics Earnings Headlines

What's the Best Way to Lower RMD Taxes?
Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain retirement accounts. Without the right strategy, these withdrawals can significantly increase your tax bill and shrink your nest egg. SmartAsset outlines six strategies that could help reduce your RMDs and potentially lower your tax burden. Their free tool can match you with vetted fiduciary financial advisors in your area—professionals legally bound to act in your best interest.tc pixel
See More CARGO Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CARGO Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CARGO Therapeutics and other key companies, straight to your email.

About CARGO Therapeutics

CARGO Therapeutics (NASDAQ:CRGX), a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

View CARGO Therapeutics Profile

More Earnings Resources from MarketBeat